trending Market Intelligence /marketintelligence/en/news-insights/trending/nfdubq3_h4mf-zhj9xjuna2 content esgSubNav
In This List

Precision oncology company Guardant Health closes $273.1M IPO

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook


Precision oncology company Guardant Health closes $273.1M IPO

Guardant Health Inc., a precision oncology company, has closed its IPO of 14,375,000 common shares at $19 each for gross proceeds of about $273.1 million.

The shares issued in the IPO include 1,875,000 additional shares of common stock sold pursuant to the full exercise of the underwriters' overallotment option, Guardant said in its Oct. 9 news release.

The healthcare equipment company's shares began trading on The Nasdaq Global Select Market on Oct. 4 under the ticker symbol GH.

J.P. Morgan Securities LLC and BofA Merrill Lynch acted as joint book-running managers, while Cowen and Co. LLC, Leerink Partners LLC and William Blair & Co. LLC acted as co-managers for the IPO.

Redwood City, Calif.-based Guardant Health offers noninvasive cancer diagnostics as well as liquid biopsy tests for advanced stage cancer.